Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Lilly buys cash-strapped Adverum for eye disease gene therapy
Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.
James Waldron
Oct 24, 2025 9:25am
Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist
Oct 24, 2025 9:15am
Sanofi drops toddler RSV vaccine after ph. 3 heads for failure
Oct 24, 2025 7:00am
Inhibrx intends FDA submission after phase 2 bone cancer win
Oct 24, 2025 6:40am
Fierce 15: Where are they now?
Oct 24, 2025 9:00am
Former Aurion chief vaults to Valitor—Chutes & Ladders
Oct 24, 2025 8:30am
More News
Fierce Healthcare
Government shutdown updates: CMS recalls furloughed workers
Oct 23, 2025 1:00pm
Regeneron does 180 on 2seventy lymphoma CAR-T
Oct 23, 2025 10:57am
Nobel winner turns rogue T cells into their own treatment
Oct 23, 2025 10:35am
Ventyx's CV drug rapidly reduces cardio risk biomarker
Oct 23, 2025 9:45am
See more stories